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In this issue of the ERJ, Erkens1 et al present experience and results of long term data 
(1993-2013) in the recording and reporting of latent tuberculosis (TB) infection (LTBI) 
management from the Netherlands. The authors report a high rate of initiation (77%) 
among the 37,729 eligible persons and a high rate of treatment completion (82%). Valid 
and complete data were available on almost all (96%) persons who started treatment 
due to the use of a technically sound notification system supported by a legal 
framework and standardized indicators1. These findings are important additions to the 
renewed focus and call to address LTBI, which is considered as the reservoir for virtually 
all TB cases2,3. Other renewed efforts include the establishment of a WHO Global Task 
Force to raise the profile of programmatic management of LTBI, including monitoring 
and evaluation of implemented activities, as well as promoting research.  
 
The management of LTBI is a key component of the WHO End TB  Strategy4, which is 
critical to the advancement of TB control, particularly when TB elimination efforts are 
pursued5. Modelling showed that protection of  8% of persons with LTBI each year from 
developing active TB disease could result in 14 fold decrease of the global incidence of 






Two-prong global approach:  
WHO has issued global recommendations on the treatment of LTBI for people living with 
HIV7 and for children aged less than 5 years old who are close contacts of a pulmonary 
TB case8.   Additionally, WHO recommends the management of LTBI among at risk 
populations in upper-middle and high-income countries with an estimated TB incidence 
rate of less than 100 per 100 000 population9. In these countries, systematic LTBI testing 
and treatment is strongly recommended for a wider range of clinical risk groups: 
patients with silicosis, patients initiating anti-tumour necrosis factor (TNF) treatment, 
patients on dialysis, and patients preparing for organ and hematologic transplantation. 
This two-prong approach and the tailored recommendations on diagnosis and 
treatment are presented in table 1.  
 
Barriers for programmatic management:  
The programmatic management of LTBI should consider the underlying epidemiology of TB, the 
burden of LTBI among risk groups, the availability of national policies and surveillance as well as 
effective health service delivery system and resources10. However, there is a gap between the 
existence of a policy and the actual implementation of diagnosis and treatment of LTBI11. 
Furthermore, recommendations contained in national guidelines from low TB incidence 
countries differ in selection of risk groups and test methods as well as on treatment options,12 
while in some high TB burden countries restrictive national policies impede the implementation 
of treatment for LTBI13. Among people living with HIV in high TB burden settings significant 
barriers were present at different levels. In particular, at programme level negative attitudes of 
managers and prominent opinion leaders - primarily due to a concern about development of 
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drug resistance13 - prevented implementation of LTBI treatment, while at service delivery level 
lack of experience, knowledge and clarity on the benefits of preventive therapy and existing 
guidelines by health workers hampered its utility14. Increased risk of development of drug 
resistance following treatment for latent TB has not been established 9,15.  
 
The lack of a gold standard for LTBI diagnosis and imperfection of the acceptable tests to predict 
progression to active TB 16,17, and long-winded treatment12 are key elements in compromising   
programmatic management of LTBI. The tuberculin skin test is widely used and inexpensive but 
it has poor sensitivity in immunocompromised people18,  and is subject to cross reactivity with 
environmental non-tuberculosis mycobacteria16.  Interferon-gamma release assays measure in-
vitro effector T-cell responses to two immunogenic M. tuberculosis antigens [6-kDa early 
secretory antigenic target (ESTA-6) and 10-kDa culture filtrate protein (CFP-10)], which are not 
found in BCG and most non-tuberculous mycobacteria.  However, these tests are expensive, 
requiring equipment and infrastructure 19.  A novel M. tuberculosis specific skin test, C-Tb, that 
contains ESAT-6 and CFP-10 antigens has been developed and shown to have improved 
specificity 20 and sensitivity21 than tuberculin skin test. However, the utility of this novel skin test 
has yet to be investigated for the diagnosis of latent TB infection.  
 
Critical bottlenecks for programmatic management of LTBI include fragmented organization of 
services for the identification of individuals, for testing and treating of eligible persons, as well 
as recording, reporting and following up of patients. For example, in most low TB burden 
countries, LTBI interventions among contacts are usually carried out by Public Health Services 
while a wide spectrum of clinical services handle LTBI management in clinical risk groups: 
infectious diseases services for people living with HIV; nephrology units for patients awaiting 
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dialysis; rheumatology units for candidates for anti-TNF therapy; pneumology units for patients 
with silicosis; and a variety mix of other specialties for candidates who will undergo 
transplantation.  The lack of standardised indicators and case definitions applicable across these 
services impedes functional and integrated monitoring and evaluation systems for 
programmatic management of LTBI. A recent survey performed by the European Respiratory 
Society (ERS) and WHO among 31 European countries shows that only 6 countries were able to 
report LTBI treatment completion rates, which ranged between 40 and 88%22. The role and 
feasibility of LTBI management among asylum seekers has also been raised in the face of recent 
influx of migrants to Europe,  presenting another programmatic challenge23.  
 
Solutions for programmatic management: 
 
The implementation of the programmatic management of LTBI requires establishing national 
policies and legal frameworks as well as close collaboration and harmonization across the 
different services9. This was illustrated by the experience of Erkens et al in the Netherlands that 
the adoption of the policy and legal framework coupled with the centralized web-based 
integration of the reporting systems with ongoing evaluation of its performance including 
clarifying the case definitions has been instrumental for the success of the programme1.  Their 
ability to report the management of LTBI in clinical at risk groups such as anti-TNF treatment 
candidates is particularly encouraging, and reflects the intensified collaboration between the 
municipality health and clinical services.   
 
While there is no current mechanism to capture the provision of treatment for LTBI globally for 
at risk populations and child contacts, there has been a burgeoning experience in the global 
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monitoring of the provision of isoniazid preventive treatment among people living with HIV 
(Figure 1).  This was possible by standardizing the definition of the indicator to measure, the 
number of adults and children living with HIV who are started on treatment for LTBI expressed 
as a percentage of the total number newly enrolled adults and children in HIV care during the 
reporting period24 and mainstreaming this indicator to the existing HIV monitoring systems of 
WHO and UNAIDS25. This was also enabled by the implementation of a four symptom-based 
simplified algorithm that has a negative predictive value of more than 98%7. It is estimated that 
half of the people living with HIV who are newly enrolled into HIV care will fulfil this criteria and 
hence are eligible for TB preventive treatment26.  
 
It is, therefore, essential to develop standard indicators to accelerate and monitor the global 
implementation of programmatic management of LTBI particularly for child contacts and other 
at risk populations. Such efforts should be based on a clear definition of numerators and 
denominators as well as the source of information and responsible services. Similarly, simplified 
algorithms should be used and developed to advance the programmatic management of LTBI 
among at risk populations including child contacts. Estimating targets for eligible candidates for 
LTBI testing and treatment will be useful for programme management. These efforts will help to 
monitor the global progress in the implementation of programmatic management of LTBI.  
 
Establishing effective systems for client education on adherence and clinical monitoring of 
adverse events, as well as supplying diagnostic tests and the drugs are other crucial steps. 
Furthermore, establishing continuous surveillance and evaluating the impact of the 
programmatic management is important as well. Programmes should design flexible 
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interventions that are tailored to respond to the local context and needs of the population to 
ensure adherence to, and completion of, LTBI treatment. 
 
Operational research efforts to enable the effective delivery of the intervention based on 
context and disease epidemiology need to be integral part of programmatic management of 
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Table 1.  Summary table of WHO recommendations for LTBI programmatic management based on category of countries 
Country groups Indicated at risk populations 
(strong recommendations) 
Testing algorithm Treatment options 
 
 
High-income and upper middle-
income countries with an 
estimated TB incidence rate of 
less than 100 per 100 000 




People living with HIV 
 
Adults and children who are household 
contacts of pulmonary TB cases. 
 
Clinical indications: patients with 
silicosis; patients initiating anti-TNF 
treatment; patients on dialysis; patients 
preparing for organ or haematologic 
transplantation 
 
Exclude active TB using TB investigations 
according to national guidelines. 
 
A positive IGRA or TST result is required to 
diagnose LTBI. 
6 months daily isoniazid 
 
9 months daily isoniazid 
 
3 months weekly rifapentine plus isoniazid 
 
3 to 4 months daily  isoniazid plus rifampicin 
 
3 to 4 months daily  rifampicin 
Resource-limited and other high 
and middle-income countries 
with an estimated TB incidence 
rate of more than 100 per 100 
000 population (High TB 
burden) 
 
People living with HIV 
 
Children under 5 years of age who are 
household contacts of a pulmonary TB 
case. 
Exclude active TB using TB investigations 
according to national guidelines 
 
An LTBI test is not required prior to LTBI 
treatment, but is encouraged for people living 
with HIV. 
 
IGRA should not replace TST. 






Figure 1. Number of people living with HIV initiated on isoniazid preventive therapy globally (blue) and in the Africa region (red) 
between 2002-2014 
 
 
 
 
